Tandem Diabetes Care (TNDM) Cash from Investing Activities Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -253.01% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -11.91% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -41.67% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -6.88% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -472.46% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | -16.93% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -111.03% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | -40.94% |
| 10 | Tandem Diabetes Care | 1.31 Bn | 739.55 Mn | 136.79 Mn | -95.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -95.07% |
| Dec 31, 2025 | -34.23% |
| Sep 30, 2025 | 51.10% |
| Jun 30, 2025 | 109.11% |
| Mar 31, 2025 | 20.91% |
| Dec 31, 2024 | 27.35% |
| Sep 30, 2024 | 20.23% |
| Jun 30, 2024 | 62.05% |
| Mar 31, 2024 | 6.03% |
| Dec 31, 2023 | 34.72% |
| Sep 30, 2023 | 29.39% |
| Jun 30, 2023 | 26.90% |
| Mar 31, 2023 | -40.94% |
| Dec 31, 2022 | 54.83% |
| Sep 30, 2022 | 13.88% |
| Jun 30, 2022 | 34.51% |
| Mar 31, 2022 | 88.33% |
| Dec 31, 2021 | -126.73% |
| Sep 30, 2021 | 5.74% |
| Jun 30, 2021 | -32.53% |
| Mar 31, 2021 | 13.80% |
| Dec 31, 2020 | -247.66% |
| Sep 30, 2020 | -726.63% |
| Jun 30, 2020 | -318.99% |
| Mar 31, 2020 | 132.86% |
| Dec 31, 2019 | -87.28% |
| Sep 30, 2019 | -79.71% |
| Jun 30, 2019 | -120.51% |
| Mar 31, 2019 | 35.28% |
| Dec 31, 2018 | -40.00% |
| Sep 30, 2018 | -82.32% |
| Jun 30, 2018 | -353.43% |
| Mar 31, 2018 | 19.55% |
| Dec 31, 2017 | -29.84% |
| Sep 30, 2017 | 74.74% |
| Jun 30, 2017 | -13.03% |
| Mar 31, 2017 | 27.75% |
| Dec 31, 2016 | 39.18% |
| Sep 30, 2016 | 61.72% |
| Jun 30, 2016 | 73.96% |
| Mar 31, 2016 | -5.30% |